Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis (SEPTIFAST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00561639|
Recruitment Status : Completed
First Posted : November 21, 2007
Last Update Posted : July 9, 2010
|Condition or disease|
|Hematologic Diseases Sepsis|
This study has double purpose :
- To compare the results obtained from the SeptiFast system with the results from classical microbiological sampling, in particular hemoculture, for immunosuppressed patients presenting sepsis.
- To perform a blind assessment of the benefit of septiFast care of these patients.
|Study Type :||Observational|
|Actual Enrollment :||76 participants|
|Official Title:||Benefit of Septifast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis|
|Study Start Date :||December 2007|
|Actual Study Completion Date :||November 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00561639
|University Hospital of Grenoble|
|Grenoble, France, 38043|
|Principal Investigator:||TIMSIT Jean-François, PU/PH||University Hospital, Grenoble|